$-0.19 EPS Expected for Biocept, Inc. (BIOC)
March 14, 2018 – By Louis Casey
Analysts expect Biocept, Inc. (NASDAQ:BIOC) to report $-0.19 EPS on March, 28 after the close.They anticipate $0.08 EPS change or 29.63 % from last quarter’s $-0.27 EPS. After having $-0.20 EPS previously, Biocept, Inc.’s analysts see -5.00 % EPS growth. The stock increased 9.59% or $0.03 during the last trading session, reaching $0.36. About 20.87 million shares traded or 1039.51% up from the average. Biocept, Inc. (NASDAQ:BIOC) has declined 31.06% since March 15, 2017 and is downtrending. It has underperformed by 47.76% the S&P500.
Biocept, Inc. (NASDAQ:BIOC) Ratings Coverage
Among 3 analysts covering Biocept Inc (NASDAQ:BIOC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biocept Inc had 4 analyst reports since August 19, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, June 6 by Roth Capital. H.C. Wainwright initiated Biocept, Inc. (NASDAQ:BIOC) rating on Wednesday, August 19. H.C. Wainwright has “Buy” rating and $4 target.
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $22.89 million. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.
Another recent and important Biocept, Inc. (NASDAQ:BIOC) news was published by Prnewswire.com which published an article titled: “Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and …” on March 12, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.